$QNCX Investors: We are pleased to participate at the British Paediatric Neurology Association 2026 Annual Meeting with a poster presentation highlighting previously published safety data from the long-term treatment of children with A-T. Learn more here: https://t.co/SHh49IB4Ps
$QNCX Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
One month to go and I expect very positive results. Remember this opens up many other diseases that this platform will be able to go after. This is as much about a platform as it is this one disease. That isn’t priced into the stock at all. Positive data on this disease pushes this over $20, then other indications started getting priced in as potential and that pushes us much much higher
One month to go and I expect very positive results. Remember this opens up many other diseases that this platform will be able to go after. This is as much about a platform as it is this one disease. That isn’t priced into the stock at all. Positive data on this disease pushes this over $20, then other indications started getting priced in as potential and that pushes us much much higher
Today feels like yesterday, SPY green while a bunch of my stuff is tanking for whatever reason.
$OCUL standout strength though. $QNCX some buyers again also.
CEO Dirk Thye recently received 1 million in options (4 year vest, strike of $3.08 - ATM). Board members have opted to receive retainers and compensation in all options, a break from the past where it was a mix of options + cash.
Incentives are aligned here.
CEO Dirk Thye recently received 1 million in options (4 year vest, strike of $3.08 - ATM). Board members have opted to receive retainers and compensation in all options, a break from the past where it was a mix of options + cash.
Incentives are aligned here.
.. we get a powerful result. I can see why management is so bullish. It would be hard to argue why a clinician would not be willing to offer a therapy with nearly 3x the potency for a young family devastated by the diagnosis of AT.
If QNCX can repeat the results from the 6-9 age group, this should translate to an approximate 2.5-3.0x MORE POWERFUL treatment than IntraBio's recent results.
Translating (and it is an approximation) IntraBio's SARA score and the ATTeST mICARS score to the RmICARS...
Bullish $QNCX.
Some perceive IntraBio's recent phase 3 as a threat to QNCX's upcoming top-line results. I would argue that knowing IntraBio's results, the forthcoming QNCX top-line has been de-risked.
@fcminaker Agreed and Dirk said so in above clip — "ten years ago". But good example of a biotech's journey with a happy ending that touches $QNCX so what if even remotely
Totally missed this! Goddammmnn!!
$QNCX CEO/CMO and COO are both met at $CDTX that recently got acquired for $9.2 billion by Merck! Wow!
Less bearish now.
$XBI
Listen around 7 minute mark 👇
Listen in to a recent conversation Quince’s CEO & CMO Dr. Dirk Thye had with Max Brennan at The BioHub Podcast. Check it out here:
https://t.co/zI17BQLhlN
$QNCX #biotech#raredisease#innovation
Woah! $QNCX team is pretty much $CDTX! Wow! Had no idea. Quince CEO/CMO Thye was Cidara's first CMO! And that's where he met QNCX COO Brendan Hannah, wow!
Daammmnn!!
$XBI
Ph3 readout anytime next month
Listen in to a recent conversation Quince’s CEO & CMO Dr. Dirk Thye had with Max Brennan at The BioHub Podcast. Check it out here:
https://t.co/zI17BQLhlN
$QNCX #biotech#raredisease#innovation
Listen in to a recent conversation Quince’s CEO & CMO Dr. Dirk Thye had with Max Brennan at The BioHub Podcast. Check it out here:
https://t.co/zI17BQLhlN
$QNCX #biotech#raredisease#innovation
$QNCX
More Form 4s today -- this time Thye and Hannah.
Granted they're all options, make what you will.
Interesting they're from just today with greater strike price than last batch of Form 4s 🤔🤔🤔 hmmm
$XBI asymmetrical bet binary event